GSK and Pfizer's adjacent booths at BIO in June (Kyle LaHucik for Endpoints News)
June 21, 2023 10:33 AM EDTUpdated 03:38 PM
R&D

GSK, Pfiz­er present key dura­bil­i­ty da­ta for RSV shots, as CDC pan­el scru­ti­nizes ri­val vac­cines

Andrew Dunn

Senior Biopharma Correspondent

GSK and Pfiz­er pro­vid­ed the first looks on Wednes­day at how long-last­ing pro­tec­tion from their res­pi­ra­to­ry syn­cy­tial virus vac­cines could be for old­er adults, pre­sent­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times